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Abstract
Background: Assembly of recombinant capsid proteins into virus-like particles (VLPs) still represents an interesting
challenge in virus-based nanotechnologies. The structure of VLPs has gained importance for the development and
design of new adjuvants and antigen carriers. The potential of Tobacco etch virus capsid protein (TEV CP) as adjuvant
has not been evaluated to date.
Findings: Two constructs for TEV CP expression in Escherichia coli were generated: a wild-type version (TEV-CP) and a
C-terminal hexahistidine (His)-tagged version (His-TEV-CP). Although both versions were expressed in the soluble
fraction of E. coli lysates, only His-TEV-CP self-assembled into micrometric flexuous filamentous VLPs. In addition,
the His-tag enabled high yields and facilitated purification of TEV VLPs. These TEV VLPs elicited broader IgG2-
specific antibody response against a novel porcine reproductive and respiratory syndrome virus (PRRSV) protein
when compared to the potent IgG1 response induced by the protein alone.
Conclusions: His-TEV CP was purified by immobilized metal affinity chromatography and assembled into VLPs,
some of them reaching 2-μm length. TEV VLPs administered along with PRRSV chimeric protein changed the
IgG2/IgG1 ratio against the chimeric protein, suggesting that TEV CP can modulate the immune response against
a soluble antigen.
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Findings
The structural proteins of some viruses occasionally
mimic the three-dimensional nature of an actual virus
while lacking the virus genome packaged inside its cap-
sid [1]. These structures, also called virus-like particles
(VLPs), apart from bearing self-assembly properties, fea-
ture highly ordered structure and surface repetitiveness,
making them good candidates for the development of
vaccines and epitope presenting platforms [2]. The up-
surge of these applications has driven the cloning,
expression and purification of virus structural compo-
nents in a wide range of host systems (reviewed by
Zeltins [3]). However, in most cases the self-assembly
of viral capsid proteins (CPs) into VLPs still remains a
challenge [4].
We previously attempted to explore the potential of
Tobacco etch virus (TEV) particles as an adjuvant and
our findings suggested that TEV induce both humoral
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and cellular response without the need of any other
stimulus [5]. However, the use of plant viral infectious
particles poses additional safety and environmental chal-
lenges [6]. By 1990s, research on Johnson grass mosaic
virus (JGMV) CP led to propose the use of chimeric
potyvirus-like particles for epitope carrying or display
taking advantage of particle features, as reviewed by
Jagadish and others [7]. For the first time, Jagadish and
others [8] successfully expressed in a recombinant sys-
tem (E. coli) the JGMV CP that assembled into virus-like
particle structures. Since then, the list of VLP assembly
from E. coli-expressed potyviral CPs has been extended
to Potato virus Y (PVY) [9], Plum pox virus [10], Pepper
vein banding virus [11], Papaya ringspot virus [12] and
TEV [13]. Interestingly, none of these potyviral CPs were
expressed as a fusion to a Histidine tag, perhaps based
on the rationale that this tag would compromise CP self-
assembly. In the current report we investigated whether
TEV CP VLPs can be assembled from Histidine-tagged
TEV CP, produced and purified at high level from E. coli
cultures. We also evaluated the potential use of TEV CP
VLPs as an adjuvant for a novel porcine respiratory and
reproductive syndrome virus (PRRSV) chimeric protein.
Two capsid protein versions, TEV-CP and His-TEV-
CP, were produced and recovered from soluble fraction
of E. coli lysates. For generation of the TEV CP expres-
sion constructs, tev cp gene (GenBank: JX512813.1)
modified to contain a glycine codon at 5′- end for facili-
tating subsequent cloning and codon-optimized for im-
proving E. coli expression was synthetically obtained
(GenScript, USA). NcoI and XhoI recognition sites were
introduced at 5′- and 3′- ends, respectively, by PCR for
subsequent ligation into IPTG-inducible expression vec-
tor pET28a + (Merck-Millipore, Germany). A stop codon
upstream of XhoI recognition site was added in the
TEV-CP version, which would result in a protein with-
out the His-tag. The cloning procedures were performed
as described previously [14]. The constructs were mobi-
lized to BL21 (DE3) E. coli expression strain and IPTG-
induced cultures were analyzed for TEV CP expression.
Western blot revealed a band corresponding to ~ 31 kDa
for each version of the TEV CP (Fig. 1a), similar to the
Fig. 1 Analysis of TEV CP proteins expression in E. coli lysates and purification. The cells were cultured in Terrific Broth medium (Sigma-Aldrich,
USA) and grown at 30 °C, until OD600 reached 1.0. Overnight induction was performed at 20 °C. 1 mM IPTG was used as inducer and cells were
lysed by sonication in 20 mM Tris, pH 8.0 (matrix buffer, MB), 500 mM NaCl. a Immune detection analysis of TEV CP proteins using anti-6xHisTag
antibody (Roche, Switzerland) for western blot (WB) and anti-TEV antibody (Agdia, USA) for ELISA. b Analysis of the purification process of His-TEV-CP
by 12% SDS-PAGE loading 10 μl of sample per lane. The purification process was performed using His Trap HP IMAC 1 ml columns (GE-Healthcare,
USA). Total soluble protein (TSP) in MB, 500 mM NaCl and 10 mM imidazole was loaded into the column. The flow-through (FT) was collected. Washing
steps were performed in MB, 40 mM imidazol, and NaCl gradient (adjusted every 5 ml at 200, 400, 600 and 800 mM). The wash FT (WFT) was collected
in 4 fractions, respectively. The proteins were eluted using MB, 100 mM NaCl and 500 mM imidazol. The elution FT (EFT) was collected in 6 fractions of
1 ml each. c Analysis of purified His-TEV-CP by 12% SDS-PAGE and WB using anti-His antibody loading 10 μl of sample per lane. The first two fractions
of EFT were prepared in MB, 500 mM NaCl, using 3 kDa Amicon Ultra centrifugal filter devices (Merck-Millipore, Germany). Protein concentration was
estimated against a BSA curve using Bradford reagent
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TEV CP estimated mass of 30.2 kDa by CLC Main
Workbench (Qiagen, Denmark). As assessed by ELISA,
His-TEV-CP expressed at higher level compared to the
non-tagged version (Fig. 1a).
For obtaining VLPs from TEV CP soluble non-tagged
version, lysates were treated with 4% (w/v) PEG 8000 for
1.5 h at 4 °C with constant shaking and left for 1 h at
room temperature (22 ± 2 °C). Then, the sample was
centrifuged at 4 °C, for 20 min, at 2,370 × g and the pre-
cipitate was solubilized overnight in 10 mM Tris-HCl
buffer, 300 mM NaCl, 10 mM EDTA, pH 7.4. Samples
were centrifuged at 4 °C, for 20 min, at 2,370 × g and
VLP-enriched supernatants were passed through a
100 kDa MWCO Amicon Ultra-4 filtration centrifugal
unit (Merck-Millipore, Germany). The estimated yield of
this non-tagged version was 1.2 mg/l of culture, as
assessed by densitometric analysis, due to presence of
several proteins belonging to the expression host that
also precipitated with PEG. On the other hand, the
His-tagged version was purified by Ni2+ affinity chro-
matography. Analysis of purification fractions showed
recovery of partially purified His-TEV-CP protein
(Fig. 1b). Larger and shorter forms of TEV CP were ob-
served in purified preparations of His-TEV-CP version,
which might correspond to dimers and proteolysis
byproducts, respectively (Fig. 1c). The yield of purified
TEV CP was calculated at 10 mg/l of culture, as esti-
mated using Bradford reagent against a BSA curve.
Final preparations were stable for months when main-
tained at 4 °C in matrix buffer (see Fig. 1 legend) with
500 mM NaCl.
For assessing TEV CP VLPs formation, transmission
electron microscopy (TEM) was performed (Fig. 2a).
The micrographs revealed that His-tagged TEV CP
version assembled into rod-shaped VLPs in the range of
20 nm to 2 μm, in contrast to non-tagged TEV CP ver-
sion, where particles around 50 nm or shorter were
observed. The mean length of His-tagged TEV CP VLPs
was 553 nm. VLPs of less than 500 nm length repre-
sented 53% of all particles analyzed, while VLPs in the
ranges of 500-1000 nm and more than 1000 nm repre-
sented 29.5 and 17.5%, respectively. Additionally, puri-
fied His-tagged TEV CP VLPs were analyzed for the
presence of nucleic acids. For this, VLPs were denatured
in protein loading buffer containing 2% sodium dodecyl
sulfate, electrophoresed in agarose gel supplemented
with SYBR-Safe (Thermo Fisher Scientific, USA) and nu-
cleic acids were visualized with Gel Doc EZ System
(BioRad, USA) using a blue light tray; same gel was sub-
sequently stained with Coomassie brilliant blue solution
for protein detection. Figure 2b shows the presence of
nucleic acids that co-localize with TEV CP protein,
which is typical of viruses and VLPs and is consistent
with the findings of Kalnciema et al. [15], who found CP
mRNA, 16S rRNA and 23S rRNA in E. coli-expressed
potato virus M (PVM) VLP preparations. Nonetheless,
Fig. 2 TEM analysis of VLP assembly of non-tagged and His-tagged TEV CP versions. a The samples were adsorbed on Formvar-coated copper
grids and negatively stained with 2% uranyl acetate aqueous solution. The grids were examined using TEM JEM-100C (JEOL, Japan) at an accelerating
voltage of 80 kV. TEV-CP lysate: TSP of TEV-CP preparation at 100,000x magnification; His-TEV-CP lysate: TSP of His-TEV-CP preparation at
100,000x magnification; TEV-CP purified: soluble fraction recovered from precipitation of TEV-CP extract using PEG 8000 3% and 500 mM NaCl
at 50,000x magnification; His-TEV-CP purified: Ni2+ affinity purified His-TEV-CP (0.4 mg/ml) in MB, 500 mM NaCl at 50,000x magnification. b
Visualization of nucleic acid content in purified His-TEV-CP VLPs sample analyzed in agarose gels. A sample of 25 μl of purified particle solution
(0.2 mg/ml) was loaded in 0.8 agarose gel in Tris, acetic cid, EDTA (TAE) buffer. The particles were treated with Laemmli sample buffer (2x) for
10 min at 95 °C. Nucleic acids in gel were visualized using SYBR Safe DNA gel stain (Thermo Fisher Scientific, USA) included in the sample with
Gel Doc EZ System (BioRad, USA) using a blue light tray. Proteins were identified with 0.1% Coomassie G-250 dye in 10% ethanol and 10%
acetic acid and destained in the same solution without Coomassie dye
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these results must be taken carefully, because the possi-
bility that RNA binds to the nickel-charged column used
in this work to purify His-tagged TEV CP can not be
ruled out [16].
In order to evaluate the adjuvant effect of TEV CP
VLPs, a novel E. coli-expressed PRRSV chimeric pro-
tein, named PRRSVchim, was used as antigen. This pro-
tein comprises PRRSV GP3 and GP4 epitopes, GP5
and M ectodomains and thioredoxin as fusion partner.
This chimeric protein was developed by our group for
swine vaccination against this virus and all its details
are included in a different manuscript that is under
preparation. Twenty-five six-week-old female BALB/c
mice (Harlan Laboratories, USA) were divided equally
into 5 groups immunized with 25 μg of His-TEV-CP (TEV
VLPs25), 10 μg of PRRSVchim (PRRSV10), 10 μg of His-
TEV-CP plus 10 μg of PRRSVchim (TEV VLPs10/PRRSV10),
25 μg of His-TEV-CP plus10 μg of PRRSVchim (TEV
VLPs25/PRRSV10), or 10 μg of PRRSVchim plus incomplete
Freund’s adjuvant (PRRSV10/IFA). Immunization protocol
as well as ELISA procedure for IgG, IgG1, IgG2a and
IgG2b isotype determinations against PRRSVchim were
performed as described by Guerrero-Rodríguez and
others [14]. As depicted in Fig. 3, PRRSVchim-specific
IgG and IgG1 isotype determinations showed an in-
crease in the antibody response elicited by PRRSVchim.
However, TEV CP VLPs plus PRRSVchim formulations
induced an IgG and IgG1 response against the
PRRSVchim protein 5-25 times lower than PRRSVchim
treatment. Conversely, PRRSVchim induced a low re-
sponse of IgG2a and IgG2b isotypes, similar to the
non-specific response to TEV CP VLPs. In addition,
the IgG2a/IgG1 ratio against PRRSVchim protein was
125 times higher in TEV CP VLPs plus PRRSVchim for-
mulations than PRRSVchim itself. The antibody re-
sponse against TEV CP VLPs was determined as well
(Additional file 1: Figure S1), with IgG1, IgG2a and
IgG2b titers of 12500, 2500 and 2500, respectively.
Fig. 3 Antibody titers produced in sera of immunized mice recognizing PRRSVchim protein. Groups were immunized with 25 μg of TEV VLPs
(TEVVLPs25), 10 μg of PRRSVchim protein (PRRSV10), 10 μg of TEV VLPs plus 10 μg of PRRSVchim protein (TEVVLPs10/PRRSV10), 25 μg of TEV VLPs
plus 10 μg of PRRSVchim protein (TEVVLPs25/PRRSV10) or 10 μg of PRRSVchim protein plus incomplete Freund’s adjuvant (PRRSV10/IFA). Immunization
was carried out via subcutaneous with 100 μl of the different preparations on days 1 and 14. Blood samples were collected by tail vein bleeding
before immunization and on day 28 after first immunization. Preimmune serum samples were checked for seronegativity to PRRSVchim protein. Serum
samples collected from the second bleeding were tested for IgG, IgG1, IgG2a and IgG2b antibody response to PRRSVchim protein by ELISA. Individual
samples belonging to the same group were pooled and diluted 1:20 followed by serial 1:5 dilution in blocking buffer. 96-well MaxiSorp Immuno Plates
(Nunc, USA) were coated with 1 μg of PRRSVchim protein per well diluted in carbonate buffer, blocked and washed. Diluted serum samples were added
to the appropriate well. After incubation and washing steps, the appropriate secondary antibody was added, HRP-donkey anti mouse IgG (Bio-Techne,
USA) diluted 1:1,000 or HRP-goat anti mouse IgG subclass 1, 2a or 2b (JIR Laboratories, USA) diluted 1:5,000. After incubation and washing
steps, 3-3′, 5-5′ tetrametylbenzidine (TMB) solution (Sigma-Aldrich, USA) was added to each well. Color development was monitored before
saturation and stopped using sulfuric acid. Absorbance was taken at 450 nm in xMark spectrophotometer microplate reader (BioRad, USA).
Results are expressed as antibody endpont titers greater than threefold the background value of preimmune sera
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This antibody profile differs from the one that
resulted after administering native TEV particles
through the intraperitoneal route [5], where the sub-
class that presented the highest increase was IgG2a.
The different immunization routes used might explain
these results. Others have reported that VLPs based
on the HIV-1 Pr55gag precursor protein induce a
predominant IgG1 subclass increase after subcutane-
ous injection [17].
Most of the research in VLP production and assembly
has been focused in plant viruses with isodiametric sym-
metry, like Cowpea mosaic virus and Cowpea chlorotic
mottle virus, the rigid rods of Tobacco mosaic virus
(TMV) and the filamentous particles of Papaya mosaic
virus (PapMV) [4]. The production of TEV CP VLPs has
been previously accomplished in a previous work [13],
where particles ranging from 90 to 750 nm in length
were observed, but level of expression was not reported.
Furthermore, the assembly of His-tagged versions of
TEV CP into VLPs was not addressed, in contrast to the
results shown here. There are two factors that can ex-
plain these disparate results: the plasmids used for ex-
pressing His-tagged TEV CP versions and expression
levels. The previous work describes the use of a plasmid
(pTrcHis B from Thermo Fisher Scientific, USA) that
adds at least 35 amino acids, including the His-tag, to
the N-terminus of the recombinant protein, com-
promising VLP formation, while the plasmid used in
the present work (pET28a + from Merck-Millipore,
Germany) just adds 8 amino acids to TEV CP, leaving
VLP assembly unaffected. Regarding the non-tagged
versions, it is possible that the expression levels of
TEV CP in the previous report reached the minimum
amount required for spontaneous assembly, which was
not the case in the present work. We hypothesized
that His-tagged TEV CP, expressed at moderately
higher levels than its non-tagged counterpart, must have
been assembled right after the elution step of Ni2+ affinity
chromatography. This could explain why a few VLPs were
observed by TEM when analyzing His-tagged TEV CP
samples before purification (Fig. 2a), however, additional
experiments must be carried out in order to confirm this
hypothesis. To our knowledge, there is no work thus far
describing the expression of a His-tagged potyviral CP
that assembles into VLPs. TMV studies have demon-
strated a pivotal role of His-tag on controlling assem-
bly of CP monomers to different virus-like structures,
like rings, discs, rods, and filamentous structures [18,
19]. However, despite the potential of affinity tags, like
hexahistidine, to facilitate process development of
proteins, these may have undesired consequences on
protein stability in solution and immunogenicity [20].
The novel PRRSVchim demonstrated to elicit potent
IgG antibody response without the need of any
adjuvant. This high immunogenicity is perhaps due to
the ability of this chimeric protein to form oligomeric
structures, as demonstrated by dynamic light scattering
(Additional file 2: Figure S2), revealing the presence of
a major peak with a mean diameter of 180 nm. How-
ever, the response is restricted to IgG1 subclass. As an
unexpected result, this antibody response against
PRRSVchim did not increase when the TEV CP VLPs
were administered along with, even when different ra-
tios of VLPs were used (Fig. 3). In contrast, TEV CP
VLPs induced a change in the IgG2/IgG1 ratio, coun-
teracting the IgG1-polarized antibody response to
PRRSVchim protein alone (Fig. 3). In mice, it is well
documented that IgG1 is related to Th2 immunity,
while IgG2a reflects a Th1 bias. In addition, soluble
proteins are generally restricted to the IgG1 isotype,
while most antiviral response belongs to IgG2a [21].
PapMV CP nanoparticles administered with trivalent
flu vaccine showed an increase in the production of
IgG1 and IgG2a against influenza virus [22]. In
addition, PRSV CP filamentous particles administered
with green fluorescent protein (GFP) induce an in-
crease in GFP-specific IgG1 and the strength of the re-
sponse depends on the ratio of VLPs used [14]. Based
on PRRSVchim antibody response, it appears that TEV
CP VLPs have a role in balancing both arms of the im-
mune system, humoral and cellular response, against
PRRSVchim. Some authors have mentioned that the suc-
cess of a PRRSV vaccine relies on its ability to induce
both neutralizing epitopes and cellular response [23].
To our knowledge there is no report in the use of TEV
CP-based particles, some of them longer than 1 μm, for
aiding the immune response against a soluble antigen.
Nevertheless, an interesting work by Kalnciema et al.
demonstrates the usefulness of PVY microparticles as
antigen carriers when translationally fused to foreign
sequences of up to 71 amino acids long [24]. Finally, it
is becoming evident that the size of the adjuvant may
have different effects on the type of the immune re-
sponse induced; it appears that microparticles promote
humoral response, whereas nanoparticles may favor the
induction of cellular response [25]. In summary, our
results demonstrate that a hexahistidine-tagged TEV
CP is successfully purified by Ni2+ affinity chromatog-
raphy and self-assembles into long VLPs. Also, these
particles contribute in balancing the immune response
elicited by a novel chimeric protein comprising se-
quences from a swine virus, which in turn is a potent
immunogen per se. The immune response of swine im-
munized with these TEV CP VLPs/PRRSVchim formula-
tions needs to be investigated. These findings highlight
the potential of TEV CP VLPs as particulate adjuvants
with immune modulation properties without the need
of antigen’s attachment.
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Additional files
Additional file 1: Figure S1. Antibody titers produced in sera of
immunized mice recognizing His-TEV-CP protein. Immunization and ELISA
procedures were conducted as described in Fig. 3 legend. Briefly explained,
serum samples corresponding to bleeding 3 of mice group immunized with
25 μg of TEV VLPs (TEVVLPs25) were tested for total IgG and isotypes IgG1,
IgG2a and IgG2b antibody response by ELISA in plates coated with with
1 μg of His-TEV-CP protein per well. Absorbance was taken at 450 nm in
xMark spectrophotometer microplate reader (BioRad, USA). Results are
expressed as antibody endpont titers greater than threefold the background
value of preimmune sera. Excel was used for data processing. (TIFF 1142 kb)
Additional file 2: Figure S2. The size distribution of purified PRRSVchim
proteins was estimated using dynamic light scattering. a) Measurements
were taken at 25 °C and at a nanoparticle concentration of 0.2 mg/ml in
Tris-HCl 20 mM, pH 8.0, NaCl 500 mM. Recording and data analysis were
taken in automated mode with the ZetaSizer Nano ZS90 and Software
version 7.11 (Malvern, United Kingdom) using the 90° scattering optics. b)
Analysis of purified PRRSVchim by 12% SDS-PAGE/Coomassie staining.
(TIFF 1142 kb)
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